Your browser doesn't support javascript.
loading
The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials.
Kang, Amy; Smyth, Brendan; Neuen, Brendon L; Heerspink, Hiddo J L; Di Tanna, Gian Luca; Zhang, Hong; Arnott, Clare; Hockham, Carinna; Agarwal, Rajiv; Bakris, George; Charytan, David M; de Zeeuw, Dick; Greene, Tom; Levin, Adeera; Pollock, Carol; Wheeler, David C; Mahaffey, Kenneth W; Perkovic, Vlado; Jardine, Meg J.
Afiliación
  • Kang A; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
  • Smyth B; University of New South Wales, Sydney, New South Wales, Australia.
  • Neuen BL; Department of Nephrology, Prince of Wales Hospital, Sydney, New South Wales, Australia.
  • Heerspink HJL; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
  • Di Tanna GL; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.
  • Zhang H; Department of Renal Medicine, St George Hospital, Sydney, New South Wales, Australia.
  • Arnott C; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
  • Hockham C; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
  • Agarwal R; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
  • Bakris G; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
  • Charytan DM; Renal Division of Peking University First Hospital, Beijing, China.
  • de Zeeuw D; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
  • Greene T; Department of Cardiology, Royal Prince Alfred Hospital, Sydney Medical School, Sydney, New South Wales, Australia.
  • Levin A; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
  • Pollock C; Indiana University School of Medicine and VA Medical Center, Indianapolis, Indiana, USA.
  • Wheeler DC; Department of Medicine, University of Chicago Medicine, Chicago, Illinois, USA.
  • Mahaffey KW; Nephrology Division, New York University Langone Medical Center, New York University School of Medicine, New York, New York, USA.
  • Perkovic V; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
  • Jardine MJ; University of Utah, Salt Lake City, Utah, USA.
Diabetes Obes Metab ; 25(8): 2151-2162, 2023 08.
Article en En | MEDLINE | ID: mdl-37161691
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Infecciones de los Tejidos Blandos / Diabetes Mellitus Tipo 2 / Inhibidores del Cotransportador de Sodio-Glucosa 2 Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans / Male Idioma: En Revista: Diabetes Obes Metab Asunto de la revista: ENDOCRINOLOGIA / METABOLISMO Año: 2023 Tipo del documento: Article País de afiliación: Australia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Infecciones de los Tejidos Blandos / Diabetes Mellitus Tipo 2 / Inhibidores del Cotransportador de Sodio-Glucosa 2 Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans / Male Idioma: En Revista: Diabetes Obes Metab Asunto de la revista: ENDOCRINOLOGIA / METABOLISMO Año: 2023 Tipo del documento: Article País de afiliación: Australia